SCHEMBL2207346

SCHEMBL2207346

COc1cccc2sc(C(=O)C3CCN(CCC4=COC=C(C5=CC=CCC5)O4)CC3)nc12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 5/20 0.36
GRM2 Q14416 3/20 0.36
CASR P41180 1/20 0.33
MAPT P10636 5/20 0.33
HTR1A P08908 4/20 0.32
HTR7 P34969 4/20 0.32
HTR2B P41595 4/20 0.32
HTR2C P28335 3/20 0.32
HTR1D P28221 3/20 0.32
ADRA2C P18825 2/20 0.32
DRD1 P21728 2/20 0.32
DRD4 P21917 2/20 0.32
HRH2 P25021 2/20 0.32
HTR1B P28222 2/20 0.32
SLC6A4 P31645 2/20 0.32
HRH1 P35367 2/20 0.32
HTR5A P47898 2/20 0.32
ADRA2A P08913 1/20 0.32
DRD2 P14416 1/20 0.32
DRD5 P21918 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2205469 0.87 CXCR6 (0.33) CASRMAPTMITFMEN1GAA
SCHEMBL2206868 0.86 MAPT (0.32) CASRMAPTMITFMEN1GAA
SCHEMBL5657157 0.77 HTR2A (0.33) HTR2AHTR7HTR2COPRM1HRH3
SCHEMBL2207339 0.71 LMNA (0.49) HTR2AGRM2HTR1AHTR7HTR2B
SCHEMBL7843048 0.71 HTR2A (0.41) HTR2AGRM2CASRMAPTMEN1
SCHEMBL5659187 0.69 KCNH2 (0.41)
SCHEMBL5774806 0.69 MEN1 (0.30) MEN1KMT2A
Hydrochloric Acid SCHEMBL5655514 0.69 KCNH2 (0.40)
SCHEMBL4682458 0.68 MEN1 (0.43) GRM2HTR7DRD4DRD2OPRM1
SCHEMBL7836502 0.68 HRH3 (0.47) HRH2HRH1HRH3KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1888574-B1 NEW ANTIBIOTIC DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-09-02 EP claimed
US-20080280888-A1 Antibiotics Derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2008-11-13 US claimed
EP-1888574-A2 NEW ANTIBIOTIC DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2008-02-20 EP claimed
WO-2006126171-A2 NEW ANTIBIOTIC DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2006-11-30 WO claimed
US-7981886-B2 Antibiotics derivatives ACTELION PHARMACEUTICAL LTD. (CH) 2011-07-19 US disclosed
EP-1888574-B1 NEW ANTIBIOTIC DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-09-02 EP disclosed
US-20080280888-A1 Antibiotics Derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2008-11-13 US disclosed
EP-1888574-A2 NEW ANTIBIOTIC DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2008-02-20 EP disclosed
WO-2006126171-A2 NEW ANTIBIOTIC DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2006-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280888-A1 Antibiotics Derivatives NR4A1, NR2C2, NR4A3 HTR2A 3373/4885GRM2 2191/4885CASR 1322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.